-
Two new hepatitis B projects of guangshengtang failed to be approved
Time of Update: 2020-04-03
However, the two new drugs (entecavir dispersible tablets and pantoprazole sodium enteric coated capsules) mentioned in the prospectus are not approved now.
-
[Qinghua birthday decade] the era of data being the king has come when China's pharmaceutical industry comes to China's "smart" pharmaceutical industry
Time of Update: 2019-10-08
In the important days of the 70th anniversary of the founding of new China and the 10th anniversary of the online line of pharmaceutical intelligence, "hospital sales data" adds another medical "wisdom" to our motherland Power.
-
First knowledge: Zhengda Tianqing and his pillar variety "entecavir
Time of Update: 2019-09-20
In the past four years of 2015-2018, Runzhong (entecavir dispersible tablets) has brought huge profits to Zhengda Tianqing with an annual sales revenue of more than 3 billion yuan.
-
Price disclosure of 50 best selling varieties including entecavir and Huoxiang Zhengqi
Time of Update: 2019-04-09
Each monitoring table includes the details and prices of the top 50 drugs in terms of sales volume.
The price collection date is March 2019.
-
318 drugs, such as atorvastatin, risuvar and entecavir, were greatly reduced in price
Time of Update: 2019-02-21
Source: procurement platform of Guangzhou Pharmaceutical Group ▍ sorting out: saibailan Banxia, February 20, Guangzhou Pharmaceutical Group procurement platform issued the notice
-
How will these 20 negotiation varieties behave in the case of volume purchase + GPO
Time of Update: 2019-01-04
Recently, the Guangzhou Public Resources Trading Center issued the notice of Guangzhou Medical Insurance Service Administration on preparing for the negotiation of the first batch
-
How to ensure the quality and supply of drugs with 4 + 7 price cut
Time of Update: 2018-12-14
On the evening of December 9, CCTV financial channel reported in detail the centralized drug purchase organized by the state
In the report, the relevant leaders
-
The first three quarters of China's biopharmaceutical revenue exceeded that of hengruian rotini, which led to an 85% increase in tumor line
Time of Update: 2018-11-27
However, the field of oncology medicine has achieved strong growth, with the sales volume of the first three quarters increasing 85% year on year, reaching 2.3 billion yuan, accounting for 14.6% of the total sales volume of the group.
-
Consistency evaluation of first-line hepatitis B drugs
Time of Update: 2018-11-23
On November 23, hisilica Pharmaceutical Group Co., Ltd
issued a notice that its wholly-owned subsidiary Sichuan hisilica Pharmaceutical Co., Ltd
(hereinafter
-
[heavyweight] 2018 hisico: revenue goes up, 58 important drugs are under research, 5 are about to be approved, and heavyweight varieties compete for consistency evaluation
Time of Update: 2018-08-23
The progress of the main research projects is as follows: Fig. 5 consistency evaluation of key research projects 03 At present, hispec has two products in the application for conformity evaluation, namely entecavir capsule and flupentixicine tablets.
-
Deep Guangpo cut another 30 kinds of drug prices! Shiguibao, Lilai, YANGSEN, etc
Time of Update: 2018-06-06
On June 5, quanyao.com released the notice on publicizing the price reduction of some traded varieties in the purchase catalogue of Shenzhen Public Hospital Pharmaceutical Group
-
When is the first-line drug TAF of hepatitis B listed in China? @State Drug Administration
Time of Update: 2018-05-25
At present, according to European EASL guidelines and American AASLD guidelines, the first-line oral antiviral therapy for chronic hepatitis B includes entecavir, TDF and TAF.
-
New drugs of two pharmaceutical enterprises in Lianyungang were rated as "generic drugs with clinical value
Time of Update: 2017-05-09
[chinapharma.com Enterprise News] recently, "the second (2016) China pharmaceutical innovation brand series selection activity" was announced, "generic drugs with clinical value
-
Entecavir has been cut 55
Time of Update: 2016-12-12
Source: Chongqing Morning Post 2016-12-12 entecavir attracted attention again in Chongqing pharmaceutical market with a maximum decrease of 55%
Two weeks ago, Chongqing
-
The market pattern of hepatitis B drugs may change
Time of Update: 2016-12-01
On November 10, 2016, FDA approved the new Gilead drug vemlidy (tenofovir alafinade, TAF) to be used in adult chronic hepatitis B virus infection patients with compensatory liver disease.
-
Wind vane of national negotiation Catalogue: Interpretation and market expectation of the first round of price reduction
Time of Update: 2016-06-24
Source: 2016-06-24 A, policy sorting and interpretation of high drug prices has become one of the important issues affecting social stability
However, the author
-
Pharmaceutical R & D, policy led "chain fission
Time of Update: 2016-03-16
Research and development ideas come from clinical and experimental data come from clinical, which can ultimately ensure the production of new drugs.
-
Domestic entecavir declared to build up the market and fought miserably
Time of Update: 2014-12-08
In terms of drug sales ranking of sample hospitals, entecavir ranked 27th in 2012, 15th in 2013, up 12 places, and has become the core product of nucleoside antiviral drugs
-
Chongqing beer will stop selling hepatitis B vaccine from now
Time of Update: 2013-09-17
Will the topic of "hepatitis B vaccine", which has caused the sharp fluctuation of Chongqing beer stock price, once again arouse the attention of the capital market? Last night
-
The fourth batch of drugs with differential pricing in Guangdong increased by 3.14% on average
Time of Update: 2013-09-12
Due to the objection of qualification conditions of nine fourth batch of drugs with differential pricing, such as entecavir, the provincial Price Bureau decided to publicize the review results of these nine drugs from yesterday to 18th.
